Series 8-Why Uneven Decisions Hurt Rare Patients More Than No Flexibility at All

When discretion exists — but isn’t applied consistently

Series 8 Law: FDASIA §901 + Accelerated Approval (21 CFR 314 Subpart H) + FDA Modernization Act 2.0-

When discretion exists — but isn’t applied consistently

Series 8 is where this series shifts from permission to accountability.

Rare patients don’t need to be convinced that flexibility exists.
They’ve seen it.

They can point to:

• approved therapies based on limited data

• creative trial designs accepted as sufficient

• decisions that weighed uncertainty, feasibility, and patient risk

And then they watch a similar program — sometimes in a similar disease — reach a completely different outcome.

Not because the science was worse.
Not because the biology failed.

But because flexibility was applied differently.

That difference matters more than almost anything else.

The Laws Behind Flexibility — and Consistency

FDASIA §901 (2012) — Contextual Benefit–Risk

FDASIA §901 requires FDA to:

• weigh severity of disease

• consider unmet medical need

• account for uncertainty

• balance risk differently when no alternatives exist

This is the backbone of rare disease flexibility.

But the law does not allow benefit–risk to change arbitrarily between programs.

Yet in practice, it often does.

Accelerated Approval (21 CFR 314 Subpart H)

Accelerated Approval allows FDA to:

• approve drugs based on surrogate or intermediate endpoints

• rely on reasonable prediction of benefit

• require post-approval studies instead of denying access

This pathway is used sometimes — and denied other times — even when:

• the biology is similar

• the surrogate is established

• the population is small

• the unmet need is severe

The harm here isn’t uncertainty.

It’s inconsistency.

FDA Modernization Act 2.0 (2022)

This law expanded what counts as evidence:

• real-world data

• registries

• natural history studies

• human-relevant models

The law removed barriers.

But it did not enforce uniform application.

So the same type of evidence may be accepted in one review — and dismissed in another.

Administrative Law Principles (APA)

The quiet but critical layer

Under the Administrative Procedure Act, FDA decisions are expected to be:

• reasoned

• consistent

• non-arbitrary

• explainable when outcomes differ

When similar programs receive different outcomes without clear explanation, the issue is no longer scientific judgment.

It’s uneven application of discretion.

What Series 8 Is Really About

Series 8 is not arguing that FDA should always approve drugs.

It’s asking something more basic and more powerful:

Why does flexibility apply in some cases, but disappear in others?

Rare patients can accept uncertainty.
They cannot navigate inconsistency.

Why Inconsistency Is So Damaging in Rare Disease

In common diseases:

• inconsistency can be corrected with another trial

• a second chance usually exists

In rare disease:

• there may be only one trial

• one sponsor

• one moment of viability

When flexibility is inconsistently applied:

• sponsors can’t predict expectations

• programs become financially unstable

• patients lose confidence in the process

Uncertainty becomes layered — scientific and procedural.

What Inconsistency Looks Like on the Ground

Patients and foundations often see patterns like:

• one disease accepts small trials; another is told they’re insufficient

• one program uses alternative endpoints; another is told endpoints must be “cleaner”

• one placebo-free design is accepted; another is deemed inadequate

• one community’s lived experience is treated as meaningful; another’s is dismissed

Each decision may be defensible in isolation.

Together, they create a system that feels arbitrary.

Why This Erodes Trust

Rare disease development depends on trust:

• patients must trust that participation matters

• sponsors must trust that expectations won’t shift late

• foundations must trust that engagement is meaningful

When flexibility is unpredictable:

• families hesitate to enroll

• sponsors hesitate to invest

• foundations struggle to advise responsibly

The cost isn’t just emotional.

It’s lost opportunity.

Why This Was Never the Goal

Flexibility was created to:

• adapt standards to feasibility

• protect rare populations from impossible demands

• preserve opportunity where certainty is unattainable

It was never meant to depend on:

• which review team you get

• which division you fall under

• how risk-averse the moment happens to be

When flexibility becomes discretionary instead of principled, its protective value collapses.

Why Patients Notice This First

Patients track outcomes across diseases because they have to.

They notice when:

• one community gets a path forward

• another is told to wait

• a third loses its only program

From the outside, these differences may look technical.

From the inside, they look like chance. Who will be picked next?

What Rare Patients Are Actually Asking For

Patients are not asking for guaranteed approvals.

They are asking for:

• consistent principles

• transparent reasoning

• predictable application of flexibility

In rare disease, predictability is not convenience.

It is survival.

Patient & Foundation Checklist

When Outcomes Feel Inconsistent Across Rare Disease Programs

Use this when similar programs reach very different conclusions.

1. Pattern Check

☐ Are similar population sizes treated differently?
☐ Are similar trial designs evaluated inconsistently?
☐ Are similar endpoints accepted in one case and rejected in another?

2. Explanation Check

☐ Has the reasoning for different outcomes been clearly explained?
☐ Is it disease-specific and transparent?
☐ Or does it rely on vague references to “totality” without clarity?

3. Timing Check

☐ Did expectations change late in development?
☐ Were patients or sponsors surprised by new requirements?

4. Impact Check

☐ Did inconsistency affect enrollment or funding?
☐ Did it destabilize the program?
☐ Did it reduce patient trust?

5. Documentation

☐ Are differences documented clearly?
☐ Is the application of flexibility traceable — or implied?

Rare & Relentless Takeaway

The greatest threat to rare disease development isn’t the absence of flexibility.

It’s inconsistent flexibility.

Because when rules exist but are applied unevenly:

• planning becomes impossible

• risk becomes unmanageable

• and patients pay the price

Rare patients don’t need guarantees.

They need to know the system will treat like situations alike.

Next — Series 9 Conclusion

What Rare Patients Are Actually Asking For — and Why This Still Matters